Route 92 Medical Announces Appointment of Blaise W. Baxter, MD, as Clinical Director


SAN MATEO, Calif., November 30, 2021 (GLOBE NEWSWIRE) – Route 92 Medical, Inc., a privately held medical technology company dedicated to becoming the performance leader in stroke intervention, announced today the appointment of Blaise W. Baxter, MD, FRCP (C), FSNIS, as clinical director, effective November 1st, 2021.

I am honored to join a leadership team focused on developing a transformative system for the treatment of acute ischemic stroke. HiPoint and Tenzing catheter technologies are positioned to revolutionize neurovascular aspiration thrombectomy for large vessel occlusions, and I am touched by the number of lives this innovation has the potential to change for the better, ”said Blaise Baxter, MD “I look forward to working closely with the Route 92 team as we advance the field of stroke intervention.

“Developing our clinical expertise and presence among leading physicians will support our efforts to successfully enroll patients in the pivotal SUMMIT MAX US trial and drive uptake of stroke treatment,” said Joey Dewayne English, MD, Ph.D, Chief Medical Officer and Route 92 Medical Co-founder. Dr. English is the medical director of neurointerventional services at California Pacific Medical Center (CPMC) in San Francisco. “Dr. Baxter will team up with my partner, Dr. Warren Kim and myself, to support physician training and education while continuing to innovate with Route 92.

“On behalf of our entire management team, I would like to congratulate Dr. Baxter on this appointment as Clinical Director,” said Tony Chou, MD, Founder and CEO of Route 92 Medical. “Given his in-depth knowledge developed over thousands of stroke procedures, as well as his widely recognized leadership in the broader field of neuroradiology, we are confident that he will be a tremendous asset to Route 92.”

Dr. Baxter is an esteemed interventional neuroradiologist with over 25 years of experience. He played a pioneering role in the research and development of mechanical thrombectomy therapy for the treatment of victims of acute ischemic stroke. As head and chairman of the Department of Radiology at the University of Tennessee, he helped make the Erlanger Health System Southeast Regional Stroke Center one of the busiest stroke centers. the United States. Dr Baxter is a past president of the Society of NeuroInterventional Surgery (SNIS) and is currently president of the SNIS Foundation. He is the recipient of a multitude of prestigious honors and awards, including Fellow of the Society of NeuroInterventional Surgery and the Baroness Erlanger Distinguished Physician Award.

About Route 92 Medical, Inc.

Based in San Mateo, California, Route 92 Medical’s mission is to become the leader in neurovascular aspiration thrombectomy. The Route 92 medical platform uses the Monopoint® system comprising an 088 catheter delivered to the neurovascular system using the specialized Tenzing® catheter. The system is designed to provide superior navigation with challenging anatomy and sturdy support, along with unmatched simplicity and speed. For more information, please visit www.r92m.com.

Investor contact:
Marissa Bych
Gilmartin Group
[email protected]


Source link

Previous Spect Receives Serial Seed Funding for Eye Disease Screening Solutions
Next 4 things to consider when getting an installment loan online